01 7Firazyr
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2019 Revenue in Millions : 272
2018 Revenue in Millions : 0
Growth (%) : N/A
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2020 Revenue in Millions : 286
2019 Revenue in Millions : 277
Growth (%) : 3
Main Therapeutic Indication : Genetic Disorders
Currency : USD
2021 Revenue in Millions : 238
2020 Revenue in Millions : 274
Growth (%) : -6
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2022 Revenue in Millions : 193
2021 Revenue in Millions : 238
Growth (%) : -19
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2023 Revenue in Millions : 150
2022 Revenue in Millions : 193
Growth (%) : -12
Main Therapeutic Indication : Rare Diseases
Currency : USD
2016 Revenue in Millions : 579
2015 Revenue in Millions : 445
Growth (%) : 30
Main Therapeutic Indication : Rare Diseases
Currency : USD
2017 Revenue in Millions : 663
2016 Revenue in Millions : 579
Growth (%) : 15
LOOKING FOR A SUPPLIER?
